|

HH2853 Tablets Clinical Trials

2 actively recruiting trials across 1 location

Also known as: HH2853

Pipeline

Phase 1/2: 2

Top Sponsors

  • Haihe Biopharma Co., Ltd.2

Indications

  • Cancer2
  • FL Lymphoma1
  • Epithelioid Sarcoma1
  • Peripheral T Cell Lymphoma1
  • Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)1

Other1 trial

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Phase 1/2

Phoenix, Arizona1 trial

Evaluate the Safety and Clinical Activity of HH2853

Mayo Clinic

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.